Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus paclitaxel/carboplatin versus placebo plus paclitaxel/carboplatin in advanced non-small cell lung cancer
ACTRN12606000316505Phase 4Terminated
- Sponsor
- Bayer
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Sorafenib + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms). Primary endpoint: Overall survival. Started Aug 2006; status: terminated.
02
Drugs
sorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12606000316505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000316505.